Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis

Figures & data

Table 1. Characteristics of patients before initial therapy: sublingual immunotherapy to HDM or omalizumab.

	study group SLIT n =9	control group omalizumab n=6	p
age mean ± SD yrs	32.7 ± 6.8	29.1 ± 6.1	0.151
women	4 (44%)	3 (50%)	0.231
TRSS± SD	1.36 ± 0.42	1.52 ± 0.72	0.452
TMS± SD	2.96 ± 1.58	3.23 ± 1.08	0.049
CTS± SD	4.32 ± 0.33	4.81 ± 0.61	0.071
the average duration of rhinitis yrs.	6.2	5.4	0.412
therapy NS AH SS	9 8 3	5 5 3	0.785
severity of LAR mild severe	0 9	1 5	0.063
asthma	1	1	0.893

Legend: SLIT- sublingual immunotherapy; TRSS – mean monthly total rhinitis score; TMS – mean monthly total medication score; CTS – mean monthly combined total score; NS – nasal steroids permanently usable; AH – permanently or periodically usable; SS – systemic steroids short-time usable.

Table 2. Changes in the studied parameters in patients and in the control group during treatment (the results before inclusion in the observation are shown in Table 1).

	subgroup continuation of SLIT n=4		subgroup SLIT+ added omalizumab n=5		omalizumab n=6
	after the first year of SLIT	after the next one year	after the first year of SLIT	after the next one year after SLIT+OM	before n=6	after 2 years, n=6
TRSS± SD	0.98 ± 0.31	0.96 ± 0.34	1.21 ± 0.53	0.6 ± 0.28*	1.52 ± 0.72	0.87 ± 0.12^
TMS± SD	2.52 ± 1.82	2.45 ± 1.21	2.25 ± 1.05	0.88 ± 0.31**	3.23 ± 1.08	1.84 ± 0.91^
CTS± SD	3.51 ± 0.69	3.42 ± 0.93	3.46 ± 0.57	1.48 ± 0.51***	4.81 ± 0.61	2.71 ± 0.86^

Legend: SD- standard deviation; SLIT- sublingual immunotherapy; OM- omalizumab; TRSS – mean monthly total rhinitis score; TMS – mean monthly total medication score; CTS – mean monthly combined total score;* the largest statistically significant decrease in TRSS for the SLIT + omalizumab group compared to other groups: SLIT continuation or omalizumab alone (p < 005);** statistically greater decrease of TMS in the SLIT + omalizumab group compared to group after SLIT continuation and to group with omalizumab alone(p < 005); *** statistically greater decrease of CTS in the SLIT + omalizumab group compared to group after SLIT continuation and to group with omalizumab alone ^ - significant statistically significant decrease in relation to the beginning of treatment..